Neoadjuvant gemcitabine therapy for breast cancer.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Breast Cancer

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CBC.2002.S.009PMID 12057045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study

  2004cited by this paper
• The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.

  2001cited by this paper
• Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

  2001cited by this paper
• Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.

  2001cited by this paper
• A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report.

  2001cited by this paper
• Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial.

  2000cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.

  1999cited by this paper
• Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life.

  1999cited by this paper
• Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

  1998cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.

  1998cited by this paper
• Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

  1998cited by this paper
• Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience.

  1997cited by this paper
• Phase II study of gemcltablne in patients with metastatic breast cancer

  1997cited by this paper
• Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.

  1997cited by this paper
• Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

  1995cited by this paper
• Advanced breast cancer: a phase II trial with gemcitabine.

  1995cited by this paper
• Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

  1995cited by this paper
• Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.

  1994cited by this paper
• Conservation surgery after primary chemotherapy in large carcinomas of the breast.

  1993cited by this paper
• Conservation Surgery After Primary Chemotherapy in Large Carcinomas of the Breast

  1993cited by this paper
• Feasibility of breast‐conservation surgery after induction chemotherapy for locally advanced breast carcinoma

  1992cited by this paper
• Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.

  1991cited by this paper
• Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

  1990cited by this paper
• Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

  1990cited by this paper
• Multimodality treatment of locally advanced breast carcinoma.

  1988cited by this paper

• Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

  2021cites this paper
• A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up

  2013cites this paper
• Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

  2007cites this paper
• State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments

  2005cites this paper
• State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments Aktueller Stand der neoadjuvanten Chemotherapie des Mammakarzinoms: Gründe, Resultate und neuere Entwicklungen

  2005cites this paper
• Neoadjuvant chemotherapy in breast cancer

  2004cites this paper
• Neoadjuvant therapy with gemcitabine in breast cancer.

  2004cites this paper
• Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.

  2004cites this paper
• Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer

  2004cites this paper
• Preoperative chemotherapy and endocrine therapy in patients with breast cancer.

  2004cites this paper
• Gemcitabine in breast cancer: future directions.

  2002cites this paper
• SECCIÓN DOCENTE Neoadjuvant chemotherapy in breast cancer

  year unknowncites this paper